Radiochemotherapy in the Management of Gastroesophageal Junction Tumours: Basic Evidences in the Neoadjuvant SettingCellini F1*, Fiore M1 and Mattiucci G2
- *Corresponding Author:
- Cellini F
Cattedra of Radiation Oncology
University Campus Bio-Medico, Rome, Italy
E-mail: [email protected]
Received date: August 29, 2013; Accepted date: October 23, 2013; Published date: October 30, 2013
Citation: Cellini F, Fiore M, Mattiucci G (2013) Radiochemotherapy in the Management of Gastroesophageal Junction Tumours: Basic Evidences in the Neoadjuvant Setting. J Gastroint Dig Syst 3:148. doi: 10.4172/2161-069X.1000148
Copyright: © 2013 Cellini F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In recent years the incidence of gastroesophageal junction (GEJ) tumors has been rapidly increasing. Many trials
have investigated the role of preoperative radiochemotherapy for this specific subgroup. In past, GEJ tumors were
sometimes considered either esophageal or gastric cancer, due to their anatomical location. Purpose of this paper is
to elucidate the benefit of radiotherapy in combination with concurrent chemotherapy in neoadjuvant setting, reviewing
the literature by the point of view of the recent classification provided for GEJ tumors.